Literature DB >> 10876745

Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices.

S N Davis1, L Vermeulen, J Banton, B S Schwartz, E C Williams.   

Abstract

The activity and sterility of reconstituted alteplase solution and the effectiveness of an alteplase dose-escalation protocol for the clearance of midline-catheter and central-venous-access device occlusions were studied. Reconstituted alteplase solution was stored at -70, -25, or 2 degrees C at concentrations of 0.5, 1, or 2 mg/mL. Durations of storage in the freezer were 0, 7, and 14 days, and durations of storage in the refrigerator were 0, 48, and 72 hours and 7 and 14 days. Samples were also assayed and cultured without prior freezing after refrigeration at 2 degrees C for 0, 48, and 72 hours and 7, 14, and 28 days. Fifty-eight pediatric and adult patients were enrolled in a separate study in which catheter clearance was initiated with alteplase 0.5 mg, and the dose was escalated to 1 and 2 mg sequentially until the catheter was cleared. The primary endpoint was restoration of catheter patency, and the secondary endpoint was the occurrence of bleeding episodes within 24 hours of alteplase administration. Catheter removal due to failure to restore patency was also documented. The activity and sterility of alteplase were maintained under all conditions studied. Fifty catheters (86.2%) were cleared with alteplase 0.5 mg, 5 (8.6%) after dose escalation to 1 mg, and 1 (1.7%) after escalation to 2 mg. The alteplase solution did not clear the occlusion in 2 catheters (3.4%): 1 had a mechanical obstruction and 1 cleared two hours after the 1-mg dose was deemed a failure. None of the six catheter removals was due to recalcitrant clots. Bleeding observed was not considered to be the result of alteplase administration. For use in clearing occlusions of venous-access devices, alteplase 0.5, 1, and 2 mg/mL retained sufficient fibrinolytic activity when stored for up to 14 days at 2 degrees C (28 days for the 0.5-mg/mL dilution) and when stored for 14 days at -70 or -25 degrees C followed by up to 14 days at 2 degrees C. The dose-escalation protocol was effective.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10876745     DOI: 10.1093/ajhp/57.11.1039

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  3 in total

1.  Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial.

Authors:  Nicola S Gittins; Yan L Hunter-Blair; John N S Matthews; Malcolm G Coulthard
Journal:  Arch Dis Child       Date:  2006-10-26       Impact factor: 3.791

2.  Intraluminal Volume Dose Alteplase for the Clearance of Occluded Peripherally Inserted Central Catheter Lines at a Long-Term Acute Care Hospital: Efficacy and Economic Impact.

Authors:  Stephen P Sapienza; Darrin R Ciaschini
Journal:  Hosp Pharm       Date:  2015-03

3.  Stability of Recombinant Tissue Plasminogen Activator at -30 °C over One Year.

Authors:  Abdulmalik Alkatheri
Journal:  Pharmaceuticals (Basel)       Date:  2013-01-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.